ClinicalTrials.gg
CompletedNCT01676116DUAL™ IIIUpdated Jan 3, 2019Results posted

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

A Phase 3 interventional study of insulin degludec/liraglutide and liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 109 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
27th of 70
438 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
30th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 30th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe, Oceania and the United States of America (USA).

The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 438 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 2 diabetes mellitus
  • Glycosylated () 7.0-9.0% (53-75 mmol/mol) (both inclusive)
  • Treatment with daily GLP-1 receptor agonist at maximum dose according to local label (i.e. 1.8 mg once daily (OD) Victoza® (liraglutide) or 10 microgram twice daily (BID) Byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg OD Victoza® (liraglutide) or 5 microgram BID Byetta® (exenatide)) in combination with a stable daily dose of metformin (equal to or above 1500 mg or documented maximum tolerated dose) for 90 days or more prior to screening visit (Visit 1)
  • (body mass index) equal to or below 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any use of oral anti-diabetic drugs (OADs) (except for metformin, pioglitazone and sulphonylurea) for 90 days or less prior to screening visit (Visit 1)
  • Use of any drug (except metformin,pioglitazone, sulphonylurea and GLP-1 receptor agonist) which in the Investigator's opinion could interfere with the blood glucose level (e.g. systemic )
  • Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator)
  • Screening calcitonin equal to or above 50 ng/l
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • Cardiovascular disorders defined as: congestive heart failure ( (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary, carotid or peripheral artery revascularisation procedures
  • Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion
  • Subjects with a , active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes mellitus), neurological, genitourinary or haematological system that in the opinion of the Investigator may confound the results of the trial or pose additional risk in administering trial products
  • History of chronic pancreatitis or idiopathic acute pancreatitis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
438 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide + OADs

    Drug: insulin degludec/liraglutide

  • Active comparator
    Liraglutide or exenatide + OADs

    Drug: liraglutide · Drug: exenatide

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.

  • Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

  • Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)

    Time frame: Week 0, week 26

Secondary outcomes

  1. Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)

    Percentage of subjects achieving HbA1c below 7.0% after 26 weeks of treatment.

    Time frame: Week 26

  2. Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)

    Percentage of responders achieving pre-defined target for HbA1c - HbA1c ≤ 6.5% (48 mmol/mol).

    Time frame: Week 26

  3. Change From Baseline in Body Weight

    Mean change in body weight after 26 weeks of treatment.

    Time frame: Week 0, week 26

  4. Change From Baseline in Fasting Plasma Glucose (FPG)

    Mean change in fasting plasma glucose from baseline, after 26 weeks of treatment.

    Time frame: Week 0, week 26

  5. Number of Severe or Minor Hypoglycaemic Episodes

    Rate (events per 100 patient years of exposure) of treatment-emergent confirmed hypoglycaemic episodes. The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes. Severe hypoglycaemia was categorised as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or PG \<3.1 mmol/L (56 mg/dL), and which was handled by the subject himself/herself, or any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or PG value \<3.1 mmol/L (56 mg/dL).

    Time frame: After 26 weeks of treatment

  6. Number of Adverse Events (AEs)

    Rate (events per 100 exposure years) of treatment-emergent adverse events (an event that had onset date (or an increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment) which occurred during the 26 weeks of treatment.

    Time frame: After 26 weeks of treatment

  7. Change From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)

    The patient related outcome is calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D individual sub-domain scores and total score are later transformed to a 0-100 scale for analysis. The mean change in scores from baseline to 26 weeks for all the individual sub domains and total scores are presented here.

    Time frame: Week 0, week 26

  8. Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).

    Mean change in diabetes treatment satisfaction questionnaire (DTSQs) scores from baseline. The scores ranged from 0 to 6. Higher total score on a 0-6 point scale indicates a general higher treatment satisfaction, whereas higher score on perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia indicate that blood glucose levels are out of the target range.

    Time frame: Week 0, week 26

08

Results

Posted Jul 9, 2018

Participant flow

The trial was conducted at 81 sites in 5 countries as follows: Australia: 5 sites; France: 7 sites; Hungary: 4 sites; Slovakia 6 sites; United States: 59 sites.

Participant flow — Overall Study
MilestoneInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Started292146
Completed276117
Not completed1629
Withdrew: Withdrawal criteria214
Withdrew: Adverse event12
Withdrew: Unclassified410
Withdrew: Protocol violation93

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
Time frame:
Week 0, week 26
Reported as:
Least squares mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
percentage of glycosylated haemoglobinInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)-1.32 ± 0.05-0.37 ± 0.07
Statistical analysis
  • Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) vs Liraglutide or Exenatide + OADs · ANCOVA · p = <0.001 · Treatment contrast: -0.94 · 95% CI -1.11 to -0.78
SecondaryResponders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)

Percentage of subjects achieving HbA1c below 7.0% after 26 weeks of treatment.

Time frame:
Week 26
Reported as:
Number · Percentage
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)
PercentageInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)75.335.6
SecondaryResponders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)

Percentage of responders achieving pre-defined target for HbA1c - HbA1c ≤ 6.5% (48 mmol/mol).

Time frame:
Week 26
Reported as:
Number · Percentage
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)
PercentageInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)6322.6
SecondaryChange From Baseline in Body Weight

Mean change in body weight after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Change From Baseline in Body Weight2 ± 3.9-0.8 ± 3.0
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Mean change in fasting plasma glucose from baseline, after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Change From Baseline in Fasting Plasma Glucose (FPG)-2.98 ± 2.28-0.6 ± 2.74
SecondaryNumber of Severe or Minor Hypoglycaemic Episodes

Rate (events per 100 patient years of exposure) of treatment-emergent confirmed hypoglycaemic episodes. The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes. Severe hypoglycaemia was categorised as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or PG \<3.1 mmol/L (56 mg/dL), and which was handled by the subject himself/herself, or any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or PG value \<3.1 mmol/L (56 mg/dL).

Time frame:
After 26 weeks of treatment
Reported as:
Number · events per 100 patient years of exposure
Number of Severe or Minor Hypoglycaemic Episodes
events per 100 patient years of exposureInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Number of Severe or Minor Hypoglycaemic Episodes281.712.1
SecondaryNumber of Adverse Events (AEs)

Rate (events per 100 exposure years) of treatment-emergent adverse events (an event that had onset date (or an increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment) which occurred during the 26 weeks of treatment.

Time frame:
After 26 weeks of treatment
Reported as:
Number · events per 100 exposure years
Number of Adverse Events (AEs)
events per 100 exposure yearsInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Number of Adverse Events (AEs)410.1364.3
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)

The patient related outcome is calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D individual sub-domain scores and total score are later transformed to a 0-100 scale for analysis. The mean change in scores from baseline to 26 weeks for all the individual sub domains and total scores are presented here.

Time frame:
Week 0, week 26
Reported as:
Mean · Scores on a scale
Change From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)
Scores on a scaleInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
TRIM-D Treatment Burden Score10.8 ± 18.85.7 ± 19.3
TRIM-D Daily Life Score6.3 ± 18.40.8 ± 18.2
TRIM-D Diabetes Management Score10.9 ± 21.34.1 ± 19.8
TRIM-D Compliance Score8.9 ± 17.34.3 ± 15.9
TRIM-D Psychological Health Score7.3 ± 14.71.4 ± 16.5
TRIM-D Total Score8.7 ± 123.1 ± 12.2
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).

Mean change in diabetes treatment satisfaction questionnaire (DTSQs) scores from baseline. The scores ranged from 0 to 6. Higher total score on a 0-6 point scale indicates a general higher treatment satisfaction, whereas higher score on perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia indicate that blood glucose levels are out of the target range.

Time frame:
Week 0, week 26
Reported as:
Mean · Scores on a scale
Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Scores on a scaleInsulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADs
Treatment satisfaction scale total3.1 ± 5.61.1 ± 5.0
Hyperglycaemia-1.8 ± 2.1-0.6 ± 1.9
Hypoglycaemia0.2 ± 1.7-0.1 ± 1.5

Adverse events

Collected over Adverse events from the first trial-related activity after the subject had signed the informed consent until the end of the post-treatment follow-up period (week 27) are reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Liraglutide +OADs—9/291 (3.1%)88/291 (30.2%)
Liraglutide or Exenatide + OADs—3/145 (2.1%)39/145 (26.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventInsulin Degludec/Liraglutide +OADsLiraglutide or Exenatide + OADs
CholelithiasisHepatobiliary disorders0/2911/145
Foot fractureInjury, poisoning and procedural complications0/2911/145
SciaticaNervous system disorders0/2911/145
Adrenal insufficiencyEndocrine disorders1/2910/145
Atrial fibrillationCardiac disorders1/2910/145
Cholecystitis acuteHepatobiliary disorders1/2910/145
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/2910/145
Lacunar infarctionNervous system disorders1/2910/145
Non-cardiac chest painGeneral disorders1/2910/145
Peripheral artery thrombosisVascular disorders1/2910/145
Most frequent other events
Most frequent other events
EventInsulin Degludec/Liraglutide +OADsLiraglutide or Exenatide + OADs
NasopharyngitisInfections and infestations26/29119/145
Lipase increasedInvestigations29/2917/145
HeadacheNervous system disorders27/2919/145
Upper respiratory tract infectionInfections and infestations18/2918/145
DiarrhoeaGastrointestinal disorders13/2918/145

Baseline characteristics

Age, Continuous
Age, Continuous(years)Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADsTotal
Mean58.3 ± 9.958.4 ± 8.858.3 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADsTotal
Female13975214
Male15371224
HbA1c
HbA1c(percentage of glycosylated haemoglobin)Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADsTotal
Mean7.8 ± 0.67.7 ± 0.67.8 ± 0.6
Body weight
Body weight(kg)Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADsTotal
Mean95.6 ± 16.695.5 ± 17.395.5 ± 16.8
Fasting plasma glucose
Fasting plasma glucose(mmol/L)Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)Liraglutide or Exenatide + OADsTotal
Mean9 ± 2.19.4 ± 2.39.1 ± 2.2
09

Study locations

109 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35216, United States
  • Novo Nordisk Investigational Site
    Goodyear, Arizona 85395, United States
  • Novo Nordisk Investigational Site
    Mesa, Arizona 85206, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85018, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Fair Oaks, California 95628, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Lomita, California 90717, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90806, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Tarzana, California 91356-3551, United States
  • Novo Nordisk Investigational Site
    Van Nuys, California 91405, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80910, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Fort Myers, Florida 33912-4343, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32204, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Miami Springs, Florida 33166, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32806, United States
  • Novo Nordisk Investigational Site
    Plant City, Florida 33563, United States
  • Novo Nordisk Investigational Site
    Winter Haven, Florida 33880, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Arlington Heights, Illinois 60004-2315, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Kalamazoo, Michigan 49048, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Saint Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68124, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Reno, Nevada 89502-0111, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Berlin, New Jersey 08009, United States
  • Novo Nordisk Investigational Site
    Flemington, New Jersey 08822-5763, United States
  • Novo Nordisk Investigational Site
    Hamilton, New Jersey 08619, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08753-2975, United States
  • Novo Nordisk Investigational Site
    Mineola, New York 11501, United States
  • Novo Nordisk Investigational Site
    North Massapequa, New York 11758-1802, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43214, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45439, United States
  • Novo Nordisk Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • Novo Nordisk Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Novo Nordisk Investigational Site
    Sumter, South Carolina 29150-1900, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Jellico, Tennessee 37762, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37212, United States
  • Novo Nordisk Investigational Site
    Tullahoma, Tennessee 37388, United States
  • Novo Nordisk Investigational Site
    Arlington, Texas 76014, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75218, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76113, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77074, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77095, United States
  • Novo Nordisk Investigational Site
    Plano, Texas 75075, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78249, United States
  • Novo Nordisk Investigational Site
    Schertz, Texas 78154, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Orem, Utah 84058, United States
  • Novo Nordisk Investigational Site
    Saint George, Utah 84790, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23219, United States
  • Novo Nordisk Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • Novo Nordisk Investigational Site
    Merewether, New South Wales 2291, Australia
  • Novo Nordisk Investigational Site
    Keswick, South Australia 5035, Australia
  • Novo Nordisk Investigational Site
    Box Hill, Victoria 3128, Australia
  • Novo Nordisk Investigational Site
    Melbourne, Victoria 3004, Australia
  • Novo Nordisk Investigational Site
    Antibes, 06600, France
  • Novo Nordisk Investigational Site
    Boulogne Billancourt, 92100, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Montigny-les-Metz, 57950, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Sète, 34200, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Budapest, 1042, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary

Showing the first 100 of 109 sites across 5 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Linjawi S, Bode BW, Chaykin LB, Courreges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10. PubMed 27943107 ↗
  • Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, Liebl A. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):144-155. doi: 10.4158/EP-2018-0284. Epub 2018 Nov 1. PubMed 30383495 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Mar 2014, 18 months.

Results were first posted in Jul 2018, 4 years 3 months after primary completion. A results delay was requested in Nov 2014.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2012
First posted
Aug 30, 2012
StartActual
Aug 29, 2012
Primary completionActual
Mar 11, 2014
CompletionActual
Mar 11, 2014
Results delay requested
Nov 20, 2014
Results first posted
Jul 9, 2018
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01676116
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 30, 2012
Start date
Aug 29, 2012
Primary completion
Mar 11, 2014
Completion
Mar 11, 2014
Results posted
Jul 9, 2018
Last update
Jan 3, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion